这是首个PD-L1抑制剂在晚期NSCLC一线治疗中取得成功的例子,也使非鳞NSCLC的一线治疗多了一个选择。 专家点评 暨南大学血液学研究所李扬秋教授和广东省人民医院吴一龙教授受邀对IMpower 130研究进行评述,该文同期发表于《柳叶刀·肿瘤》杂志—...
Crossover to atezo at PD was initially permitted for Arm B pts. Co-primary endpoints were investigator-assessed PFS and OS (ITT-WT population: EGFR-WT/ALK-negative). Secondary endpoints were OS and PFS (ITT population and by PD-L1 expression), response rate and safety. ITT population could...
Although the irAE incidence rate in the atezolizumab-containing arm (48%) is consistent with reported rates of less than or equal to 50% for PD-L1/PD-1 inhibitors from various studies,4,32-34it is higher than that observed for atezolizumab monotherapy in the TAIL (10%)35and OAK (31%)...
这是首个PD-L1抑制剂在晚期NSCLC一线治疗中取得成功的例子,也使非鳞NSCLC的一线治疗多了一个选择。 专家点评 暨南大学血液学研究所李扬秋教授和广东省人民医院吴一龙教授受邀对IMpower 130研究进行评述,该文同期发表于《柳叶刀·肿瘤》杂志——“第二波免疫联合治疗汹涌而至”。 在点评中,两位教授提出了几个需要探讨的...